New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 8, 2013
18:58 EDTSTAA, GILD, AA, SHLM, JCP, OCZ, STWDOn The Fly: After Hours Movers
UP AFTER EARNINGS: Staar Surgical (STAA), up 21% after the company announced preliminary Q1 revenue that beat current estimates... ALSO HIGHER: Gilead (GILD), up 2% after submitting an new drug application to the FDA for its hepatitis C treatment sofosbuvir... DOWN AFTER EARNINGS: Alcoa (AA), down 1.7%... A. Schulman (SHLM), down 5.8%... ALSO LOWER: J.C. Penney (JCP), down 6.8% after the company announced CEO Ron Johnson was stepping down and will be replaced by former CEO Myron "Mike" Ullman... OCZ Technology (OCZ), down 12% after the company announced it would not meet an April 8 filing deadline with the SEC... Starwood Property (STWD), down 2.6% after announcing 26.5M common share offering.
News For STAA;GILD;AA;SHLM;JCP;OCZ;STWD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
September 25, 2014
06:58 EDTAAAlcoa estimates raised ahead of earning on higher aluminum prices at Stifel
Stifel raised Alcoa's Q3 EPS estimate to 24c from 20c, vs. consensus of 20c, 2014 EPS to 70c from 67c, vs. consensus of 64c, and 2015 EPS to $1.25 from $1.05, vs. consensus of 87c, reflecting higher aluminum prices. The firm believes price strength has been due to rising demand and producer discipline. Shares are Buy rated with a $20 price target, up from $17.
September 24, 2014
09:34 EDTGILDActive equity options trading on open
Subscribe for More Information
09:28 EDTGILDGilead price target raised to $118 from $111 at Piper Jaffray
Subscribe for More Information
08:39 EDTGILDGilead's two TAF Phase 3 trials meet primary objectives
Subscribe for More Information
05:12 EDTGILDGilead submits NDA to Japan for fixed-dose combination of Ledipasvir/Sofosbuvir
Gilead Sciences announced that the company has submitted a New Drug Application, or NDA, to Japanís Pharmaceutical and Medical Devices Agency, or PMDA, for approval of an investigational once-daily fixed-dose combination of the NS5A inhibitor ledipasvir, or LDV, 90 mg and the nucleotide analog polymerase inhibitor sofosbuvir, or SOF, 400 mg for the treatment of chronic genotype 1 hepatitis C virus, or HCV, infection in adults. The data submitted in the NDA, which include a Japanese Phase 3 study showing 100 percent SVR12 rates, support the use of LDV/SOF for 12 weeks in treatment-naÔve and treatment-experienced patients with chronic genotype 1 HCV infection, including those with cirrhosis. Patients who achieve SVR12 are cured of HCV infection. If approved, LDV/SOF would simplify HCV treatment for genotype 1 patients in Japan to one daily tablet, eliminating the need for interferon and ribavirin, or RBV. LDV/SOF is currently under regulatory review in the United States and European Union.
September 23, 2014
10:54 EDTAAAlcoa initiated with a Buy at Tigress Financial
Subscribe for More Information
08:07 EDTGILDFDA Pediatric Advisory Committee to hold a meeting
Subscribe for More Information
September 22, 2014
12:59 EDTAAToyota to use aluminum for Camry hood, Automotive News says
Toyota Motor (TM) looks set to begin using aluminum instead of steel to build the hood of its widely popular Camry vehicle, according to Automotive News. The change will begin in 2018, the website quoted an unnamed source as saying, Alcoa (AA) mines aluminum. Reference Link
11:38 EDTJCPStocks with call strike movement; JCP TWTR
J.C. Penney (JCP) February 12 call option implied volatility increased 5% to 45, Twitter (TWTR) January 62.5 call option implied volatility increased 4% to 46 according to IVolatility.
09:15 EDTGILDIntercept recent weakness a buying opportunity, says Summer Street
Subscribe for More Information
September 19, 2014
11:26 EDTGILDStocks with call strike movement; TSLA GILD
Subscribe for More Information
09:37 EDTGILDActive equity options trading on open
Subscribe for More Information
06:46 EDTSTWDStarwood Property appoints Jeffrey DiModica President effective September 18
Subscribe for More Information
06:25 EDTGILDGilead granted marketing aurhotization from European Commission for Zydelig
Subscribe for More Information
06:11 EDTGILDGilead price target raised to $139 from $111 at Citigroup
Citigroup raised its price target for Gilead shares to $139 saying management looks "very optimistic" that FY15 hepatitis C treatment volumes could be up substantially over FY14 rates globally. Citi also expects recent buybacks to boost Q4 earnings substantially and that future stock buybacks will drive appreciation. The firm keeps a Buy rating on Gilead.
September 18, 2014
12:12 EDTGILDStocks with call strike movement; PIR GILD
Subscribe for More Information
12:07 EDTJCPStocks with call strike movement; JCP FB
Subscribe for More Information
08:17 EDTGILDGilead trial failure not material, says FBR Capital
Subscribe for More Information
September 17, 2014
11:52 EDTGILDStocks with call strike movement; X GILD
Subscribe for More Information
06:04 EDTGILDGilead's simtuzumab Phase 2 study for pancreatic cancer does not meet endpoint
Gilead announced results from a Phase 2 study evaluating simtuzumab, an investigational inhibitor of lysyl oxidase-like-2, in combination with gemcitabine for patients with previously untreated advanced pancreatic cancer. In the study, the addition of simtuzumab to gemcitabine did not significantly increase progression-free survival compared to placebo plus gemcitabine. There was no difference in adverse events between patients taking simtuzumab versus placebo. Simtuzumab is being evaluated in several ongoing Phase 2 trials, including for advanced colorectal cancer, myelofibrosis, as monotherapy for idiopathic pulmonary fibrosis, and for liver fibrosis. Other agents in Gileadís oncology pipeline are currently being evaluated in clinical trials for the treatment of pancreatic cancer.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use